Saniona AB (publ) (STO:SANION)
Sweden · Delayed Price · Currency is SEK | Market Cap | 1.63B -10.3% |
| Revenue (ttm) | 424.56M +25.0% |
| Net Income | 183.53M -14.4% |
| EPS | 1.31 -28.3% |
| Shares Out | 138.03M |
| PE Ratio | 9.07 |
| Forward PE | 28.23 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 274,528 |
| Open | 11.83 |
| Previous Close | 11.84 |
| Day's Range | 11.66 - 12.07 |
| 52-Week Range | 11.00 - 28.30 |
| Beta | 1.22 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 27, 2026 |
About Saniona AB
Saniona AB (publ), a clinical-stage biopharmaceutical company, focuses on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders in Ireland, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy that has completed Phase 2 clinical trial for the trea... [Read more]
Financial Performance
In 2025, Saniona AB's revenue was 434.40 million, an increase of 29.80% compared to the previous year's 334.67 million. Earnings were 284.67 million, an increase of 50.85%.
Financial StatementsNews
Saniona AB Quarterly report: Q2 2026
Saniona AB has published its Q2 2026 quarterly earnings report on August 27, 2026.
Saniona AB Transcript: R&D Day 2026
SAN2668 is advancing as a differentiated therapy for severe pediatric epilepsies, showing robust preclinical efficacy and improved tolerability. The program is well-funded through early clinical milestones, with a strategy to maximize value and address significant unmet needs in DEEs.
Saniona AB Press release: FY 2026
Saniona AB issued a press release on June 17, 2026, disclosing material business information to investors.
Saniona AB Transcript: Aktiedagarna 2026
Strong cash reserves and major licensing deals enable progression of three CNS-focused preclinical programs into phase I trials by early 2025, with results expected in the second half of 2025. The strategy emphasizes selective GABA modulators for epilepsy and depression, aiming for further partnerships and a diversified pipeline.
Saniona AB Quarterly report: Q1 2026
Saniona AB has published its Q1 2026 quarterly earnings report on May 26, 2026.
Saniona AB Slides: Corporate presentation
Saniona AB has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
Saniona AB Slides: Corporate presentation
Saniona AB has posted slides in relation to its latest quarterly earnings report, which was published on March 24, 2026.
Saniona AB Transcript: Life Science Conference 2026
Major licensing deals with Acadia and Jazz have strengthened financials and enabled a robust internal pipeline targeting CNS diseases. Multiple clinical programs are advancing, with near-term milestones expected and a strategy focused on both internal development and strategic partnerships.
Saniona AB Transcript: Life Science-dagen 2026
Strong cash reserves and major partnerships support advancement of three internal CNS programs into clinical trials, with phase I readouts expected in 2027. Selective GABA modulators target high unmet needs in epilepsy and depression, aiming for rapid growth and future phase III readiness.
Saniona AB Quarterly report: Q4 2025
Saniona AB has published its Q4 2025 quarterly earnings report on February 26, 2026.
Saniona AB Annual report: Q4 2025
Saniona AB has published its Q4 2025 annual report on February 26, 2026.
Saniona AB Quarterly report: Q3 2025
Saniona AB has published its Q3 2025 quarterly earnings report on November 27, 2025.
Saniona AB Transcript: Life Science Summit 2025
Strong financials and major partnerships support a robust CNS pipeline, with multiple assets advancing toward clinical trials in epilepsy and depression. The company targets large markets and aims for broad regulatory labels, leveraging recent high-value industry deals.